Abstract
Flurbiprofen axetil (FPA) is an injection product and a prodrug of a non-steroidal anti-inflammatory drug (NSAID). After injection, it is rapidly hydrolyzed to the active form, flurbiprofen (FP). Since frequent injections of FPA can lead to abnormal physiology, an administration strategy is necessary to ensure there is enhancement of the analgesic efficiency of FP after a single dose and to reduce the total number of doses. FP strongly binds to site II of albumin, and thus the free (unbound) FP concentration is low. This study focused on 6-methoxy-2-naphthylacetic acid (6-MNA), the active metabolite of nabumetone (a prodrug of NSAID). We performed ultrafiltration experiments and pharmacokinetics analysis in rats to investigate whether the inhibitory effect of 6-MNA on FP binding to albumin increased the free FP concentration in vitro and in vivo. Results indicated that 6-MNA inhibited the binding of FP to albumin competitively. When 6-MNA was injected in rats, there was a significant increase in the free FP concentration and the area under concentration–time curve (AUC) calculated from the free FP concentration, while there was a significant decrease in the total (bound + free) FP concentration and the AUC calculated from the total FP concentration. These findings indicate that 6-MNA inhibits the protein binding of FP in vivo. This suggests that the frequency of FPA injections can be reduced when administered with nabumetone, as there is increase in the free FP concentration associated with pharmacological effect.
Access this article
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Similar content being viewed by others
References
Arai Y, Tanaka K, Ushijima H, Tomisato W, Tsutsumi S, Aburaya M, Hoshino T, Yokomizo K, Suzuki K, Katsu T, Tsuchiya T, Mizushima T (2005) Low direct cytotoxicity of nabumetone on gastric mucosal cells. Dig Dis Sci 50:1641–1646
Bellamy N, Bensen WG, Beaulieu A, Siminovitch KA, Kraag GR, Lussier A, Ahmad S, Khanna VN, Davis P, Bell MJ (1995) A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. J Rheumatol 22:915–920
Blower PR (1992) The unique pharmacologic profile of nabumetone. J Rheumatol Suppl 36:13–19
Brier ME, Sloan RS, Aronoff GR (1995) Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. Clin Pharmacol Ther 57:622–627
Cangiano JL, Figueroa J, Palmer R (1999) Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoarthritis. Clin Ther 21:503–512
Cook ME, Wallin JD, Thakur VD, Kadowitz PJ, McNamara DB, Garcia MM, Lipani JA, Poland M (1997) Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 24:1137–1144
Dasgupta A (2002) Clinical utility of free drug monitoring. Clin Chem Lab Med 40:986–993
Davies NM (1995) Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 28:100–114
Dollery C (1999) Therapeutic drugs, 2nd edn. Churchill Livingstone, Edinburgh
Doumas BT, Watson WA, Biggs HG (1971) Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 31:87–96
Duan L, Li X (2004) Clinical application of flurbiprofen axetil injection. Chin N Drugs J 13:851–852
Freed MI, Audet PR, Zariffa N, Krishna GG, Ilson BE, Everitt DE, Brown LE, Rizzo SM, Nichols AI, Jorkasky DK (1994) Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers. J Clin Pharmacol 34:1098–1108
Friedel HA, Langtry HD, Buckley MM (1993) Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs 45:131–156
Hao J, Wang K, Shao Y, Cheng X, Yan Z (2013) Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study. J Palliat Med 16:190–192. doi:10.1089/jpm.2012.0353
Kragh-Hansen U (1981) Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 33:17–53
Lister BJ, Poland M, DeLapp RE (1993) Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 95:2S–9S
Liu ZF, Chai XQ, Chen KZ (2011) Flurbiprofen axetil enhances analgesic effect of fentanyl associated with increase in β-endorphin levels. J Anesth 25:679–684. doi:10.1007/s00540-011-1192-6
Ochi T et al (2004) A manual for medical consultation of rheumatoid arthritis. Japan Rheumatism Foundation Information Center, Tokyo
Ogata K, Takamura N, Tokunaga J, Kawai K, Arimori K, Higuchi S (2008) Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats. J Pharm Pharmacol 60:15–20
Palmer R, Weiss R, Zusman RM, Haig A, Flavin S, MacDonald B (2003) Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 16:135–139
Rahman MH, Yamasaki K, Shin YH, Lin CC, Otagiri M (1993) Characterization of high affinity binding sites of non-steroidal anti-inflammatory drugs with respect to site-specific probes on human serum albumin. Biol Pharm Bull 16:1169–1174
Setoguchi N, Takamura N, Fujita K, Ogata K, Tokunaga J, Nishio T, Chosa E, Arimori K, Kawai K, Yamamoto R (2013) A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis. Biopharm Drug Dispos 34:125–136. doi:10.1002/bdd.1829
Somasundaram S, Hayllar H, Rafi S, Wrigglesworth JM, Macpherson AJ, Bjarnason I (1995) The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 30:289–299
Subramanian M, Agrawal V, Sandee D, Tam HK, Miller WL, Tracy TS (2012) Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics 22:590–597. doi:10.1097/FPC.0b013e3283544062
Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR (1996) Studies of flurbiprofen 4′-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 52:1305–1309
Wanwimolruk S, Birkett DJ, Brooks PM (1983) Structural requirements for drug binding to site II on human serum albumin. Mol Pharmacol 24:458–463
Watanabe A, Yamakage M (2011) Intrathecal neurolytic block in a patient with refractory cancer pain. J Anesth 25:603–605. doi:10.1007/s00540-011-1141-4
Wu H, Chen Z, Sun G, Gu K, Pan Y, Hao J, Du Y, Ning J (2009) Intravenous flurbiprofen axetil can increase analgesic effect in refractory cancer pain. J Exp Clin Cancer Res 28:33. doi:10.1186/1756-9966-28-33
Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879–885
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ogata, K., Takamura, N., Tokunaga, J. et al. A novel injection strategy of flurbiprofen axetil by inhibiting protein binding with 6-methoxy-2-naphthylacetic acid. Eur J Drug Metab Pharmacokinet 41, 179–186 (2016). https://doi.org/10.1007/s13318-014-0248-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-014-0248-z